Holen Sie sich die Stockscreener-App
488.43
0.26%
-1.96
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$490.39
Offen:
$492.67
24-Stunden-Volumen:
19,824
Relative Volume:
0.01
Marktkapitalisierung:
$124.17B
Einnahmen:
$12.34B
Nettoeinkommen (Verlust:
$4.34B
KGV:
28.96
EPS:
16.8685
Netto-Cashflow:
$3.71B
1W Leistung:
+3.50%
1M Leistung:
-2.11%
6M Leistung:
+2.83%
1J Leistung:
+4.42%
1-Tages-Spanne:
$489.06
$492.99
1-Wochen-Bereich:
$465.00
$493.61
52-Wochen-Spanne:
$362.50
$533.67
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
489.22 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
693.93 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
874.99 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.64 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.46 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect? - TradingView
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Projected to Announce Quarterly Earnings on Monday - MarketBeat
OMERS ADMINISTRATION Corp Has $8.39 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Lombard Odier Asset Management Switzerland SA Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Purchases 20,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Sei Investments Co. Sells 230,797 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vertex Pharmaceuticals Incorporated $VRTX Position Reduced by Cetera Investment Advisers - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bank of Nova Scotia - MarketBeat
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Renaissance Technologies LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by PNC Financial Services Group Inc. - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 45,003 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock trades near record levels as cystic fibrosis franchise drives earnings growth - AD HOC NEWS
Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa
Vertex Pharmaceuticals Inc (VRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:478.960|Chg%:+1.600 - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:473.090| - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:477.360|Chg%:+4.270 - TradingKey
Caxton Associates LLP Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Gibbs Wealth Management Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock trades near record territory as cystic fibrosis franchise drives earnings growth - AD HOC NEWS
CI Investments Inc. Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Trust Advisors LP Has $136.85 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vertex Pharmaceuticals (VRTX) EVP Amit Sachdev receives 8,251-share equity grant - Stock Titan
Vertex stock consolidates after strong Q1 2026 revenue growth - Ad-hoc-news.de
3 Healthcare Stocks with Competitive Advantages - Yahoo! Finance Canada
Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower - Yahoo Finance
Aureus Asset Management LLC Has $3.75 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Vertex was sole bidder in high-premium Crinetics acquisition - BioPharma Dive
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex was only bidder for Crinetics in year’s second-highest M&A premium - Endpoints News
Madison Asset Management LLC Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Danica Pension Livsforsikringsaktieselskab Takes $11.67 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex-Crinetics Pharmaceuticals deal faces Australian review - MLex
ABN Amro Investment Solutions Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Andra AP fonden Has $10.67 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Former Vertex chief Jeff Leiden’s latest venture: a ‘smart’ toilet seat - The Boston Globe
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation - ChartMill
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by KBC Group NV - MarketBeat
Meeder Asset Management Inc. Buys 2,799 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19 - marketscreener.com
Dimensional Fund Advisors LP Buys 43,682 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baader Bank Aktiengesellschaft Sells 8,324 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):